AKTX Akari Therapeutics PLC

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 12b-25

 

NOTIFICATION OF LATE FILING

 

SEC FILE NUMBER 001-39290
CUSIP NUMBER 97382D 501

 

(Check One):		☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR

 

For Period Ended: September 30, 2024   ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q   For the Transition Period Ended: ________

 

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

 

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

 

 

 

PART I -- REGISTRANT INFORMATION

Akari Therapeutics, Plc

Full Name of Registrant

 

N/A

Former Name if Applicable

 

22 Boston Wharf Road FL 7

Address of Principal Executive Office (Street and Number)

 

Boston, MA 02210

City, State and Zip Code

 

 

 

 

PART II -- RULES 12B-25(b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

 

	☒	(a) The reason described in reasonable detail in Part III of this Form could not be eliminated without unreasonable effort or expense;   (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or

---

		the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and   (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

PART III – NARRATIVE

 

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

 

The Quarterly report on Form 10-Q for the period ended September 30, 2024 (“Quarterly Report”) of Akari Therapeutics, Plc (the “Company”) could not be filed on schedule due to the time and resources required for the Company to complete the closing of the Company’s previously announced merger with Peak Bio, Inc and the disclosures related thereto. The Company expects to be in a position to file the Quarterly Report within the five-day extension provided by Rule 12b-25 under the Securities Exchange Act of 1934.

 

PART IV -- OTHER INFORMATION

 

(1) Name and telephone number of person to contact in regard to this notification

 

Samir R. Patel, M.D.		(929)		274-7510
(Name)		(Area Code)		(Telephone Number)

 

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).

☒ Yes ☐ No

 

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

☐ Yes ☒ No

 

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

 

 

Akari Therapeutics, Plc

(Name of Registrant as Specified in Charter)

 

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date	November 15, 2024		By	/s/ Samir R. Patel, M.D.

Name: Samir R. Patel, M.D.

Title: Interim President and Chief Executive Officer

---

---